STOCK TITAN

Bolt Biotherapeutics (BOLT) Stock News, May-Oct 2023

BOLT NASDAQ

Bolt Biotherapeutics develops cancer immunotherapies using its Boltbody™ Immune-Stimulating Antibody Conjugate platform and myeloid-biology programs. Company updates focus on BDC-4182, a next-generation claudin 18.2 ISAC clinical candidate for gastric and gastroesophageal cancers, along with BDC-3042, a Dectin-2 agonist antibody, and preclinical ISAC programs targeting CEA and PD-L1.

Recurring news also includes clinical and preclinical data presentations, quarterly financial results, cash runway commentary, collaboration activity with Genmab and Toray, partnering process disclosures for pipeline assets, conference participation, and cost-control actions tied to the company’s oncology research and development strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.00%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.56%
Tags
none

FAQ

What is the current stock price of Bolt Biotherapeutics (BOLT)?

Bolt Biotherapeutics (BOLT) last closed at $5.65.

What is the market cap of Bolt Biotherapeutics (BOLT)?

The market cap of Bolt Biotherapeutics (BOLT) is approximately $14.7M.